|
|
 |
|
Viewing report
|
|
|
|
Guillain Barre Syndrome (GBS) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
GlobalData, May 2011, Pages: 39
Guillain Barre Syndrome (GBS) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Guillain Barre Syndrome (GBS) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Guillain Barre Syndrome market. The report identifies the key trends shaping and driving the global Guillain Barre Syndrome market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Guillain Barre Syndrome sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by GlobalData’s team of industry experts.
GlobalData’s analysis revealed that the global Guillain Barre Syndrome market was worth $370m in 2010. It is forecast to grow at a compound annual growth rate (CAGR) of 5.1% over the next seven years, to reach $520m by 2017. This is primarily attributed to the predicted increase in the prevalence of the disease.
Scope
The report provides information on the key drivers and challenges of the Guillain Barre Syndrome market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Guillain Barre Syndrome market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets.
- Analysis of the current and future competition in the seven key countries Guillain Barre Syndrome market. Key market players covered are Baxter Biotherapeutics, Grifols Biologics Inc. and CSL Behring.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Guillain Barre Syndrome therapeutics market.
- Analysis of key recent licensing and partnership agreements in Guillain Barre Syndrome market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Guillain Barre Syndrome market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Guillain Barre Syndrome market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Guillain Barre Syndrome market landscape? – Identify, understand and capitalize.
|
|
|
|
